Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Parkinson's disease: Studies on the pathology of the disease and the mechanism of action of the neurotoxin MPTP

Thesis/Dissertation ·
OSTI ID:5647254
In humans and animals, exposure to 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) causes certain clinical, pathological, and neurochemical features of Parkinson's disease (PD). MPTP is metabolized in the brain by monoamine oxidase (MAOb) to 1-methyl-4-phenylpyridine (MPP{sup +}), which is selectively accumulated and concentrated by high affinity uptake mechanisms into catecholamine neurons. We have demonstrated high affinity binding of MPP{sup +} to neuromelanin which may result in a toxic intraneuronal sequestration of MPP{sup +}. The involvement of neuromelanin is further supported by the demonstration that monkeys pretreated with chloroquine prior to the administration of MPTP are protected from MPTP induced neurotoxicity. Decreases in serotonin levels have been reported in the brains and spinal fluid of patients with both Parkinson's and Alzheimer's disease. In an effort to investigate the pathology of serotonin neurons in postmortem brain tissue from Parkinson's and Alzheimer's patients, ({sup 3}H)citalopram was characterized as a means of labeling serotonin uptake sites present on serotonin terminals.
Research Organization:
Johns Hopkins Univ., Baltimore, MD (USA)
OSTI ID:
5647254
Country of Publication:
United States
Language:
English

Similar Records